On the morning of April 3, 2021, a great cheer went up in the newly completed G-4 workshop of Zhejiang PHT Pharmaceutical Co., Ltd,  upon the moment that the first batch of HAA product is successful completed. This  means  the continuous nitration reaction production line of  HAA throughput of 1000m3/year  was commercialized successfully, and the continuous nitrification process has reached a new level.

 

Since then, PHT's "HAA continuous nitration project" has come into the stage of commercial production and operation stage from the project construction and equipment commissioning , which has taken a solid step towards the company's high-quality and innovative development.

 

The high-end drug intermediate HAA project is an intermediate of vildagliptin, a new drug to treat diabetes, for Swiss Novartis Pharmaceuticals known as an international pharmaceutical giant. PHT international, the parent company of Zhejiang PHT is a long-term partner of Novartis to provide HAA for them.

 

Compare with ordinary traditional tank nitrification reactions , the micro-channel nitrification has fundamentally reduced the safety risks and waste. The success of the "HAA project continuous micro-channel nitrification reaction" is an important milestone in PHT's development history, also a new starting point. PHT will utilize his technological advantage to improve management and economic benefits continuously with the government's industrial policy support

 

In order to celebrate this special moment and thank all employees for their unremitting efforts for this project, a jogging race was organized  around the beautiful Xianghai lake.